CTOs on the Move

American Pharmacy Cooperative

www.apcinet.com

 
American Pharmacy Cooperative is a Bessemer, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.apcinet.com
  • 5601 Shirley Park Dr
    Bessemer, AL USA 35022
  • Phone: 205.277.1007

Executives

Name Title Contact Details

Similar Companies

Hughes BioPharma Advisers

Hughes BioPharma Advisers is a Darien, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Encompass Group

For nearly a century, Encompass has been helping health care and hospitality organizations create safe, comfortable environments for patients, staff, residents and guests. Whether developing advanced hypothermia prevention products, helping hospitals contain the spread of infections, or designing interiors for new, state-of-the-art retirement communities, we offer a complete line of products, services and education programs that meet the challenges our customers face every day.

Medisiss

Medisiss is a Redmond, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arizona Hospital And Health Care Association

Arizona Hospital And Health Care Association is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.